The results of the clinical trial of the new crown vaccine of the "Pharmaceutical Speed Reader" came out with the introduction of three new hepatitis B drugs.

July 21, 2020 / Medical Information List: The results of clinical trials of two new crown vaccines are available; the application for a chinese listing in DingRiptini was accepted for treatment of gastrointestinal interstitial tumors; Beida Pharmaceuticals lost $6 billion overnight; Baiji Shenzhou and Assembly reached a partnership to introduce three HBV core inhibitors into China; and The pharmaceutical company Ming Juno acquired Syracchia... Daily fresh medicine to hear medical news, fast-reading society with you to pay attention! Part 1 Policy Brief State Council: Further relax the scope of Internet diagnosis and treatment Speed up the approval of innovative medical devices The State Council issued the "State Council General Office on the further optimization of the business environment to better service market subjects of the implementation of the opinions", clearly mentioned: under the premise of ensuring medical safety and quality, further relax the scope of Internet diagnosis and treatment, the inclusion of qualified Internet medical services in the scope of medical insurance reimbursement, the formulation of the national unified Internet medical approval standards, accelerate the approval of innovative medical devices and promote clinical application.
(General Office of the State Council) officially issued a document allowing "homogenization" to accelerate the establishment and improvement of the technical evaluation system in line with the characteristics of Chinese medicine, improve the quality of Chinese medicine preparations, and promote the high-quality development of the Chinese medicine industry, CDE organization drafted the "Technical Guidelines for the Study of Homogenization of Chinese Medicine(draft for comments).
"homogenization" means: in order to reduce the quality difference between batch of Chinese medicine preparations and achieve the expected quality target, the different batches of qualified prescription drug taste according to the appropriate proportion of the measures.
(CDE) State ministries released the village medical reform heavy signal This model of national promotion 20, Guizhou Provincial Health and Health Commission issued a message that the state ministry to the province to investigate the construction of rural doctors team work.
the National Research Group proposed that Guizhou Province is now implementing the rural doctor team construction policy (all village doctors into the county medical community establishment, "post system", increase the village medical subsidies, assessment of the village doctors directly dismissed), can be copied and promoted, for other provinces of the country to provide a good reference.
(Guizhou Provincial Health and Health Commission) the third batch of collection to come 86 standards to start information collection Shanghai Sunshine Pharmaceutical Procurement Network issued "on the development of some drug-related basic information collection work notice", on 86 standard drugs to collect relevant information, in preparation for the follow-up collection.
(Shanghai Sunshine Pharmaceutical SourdIng Network) Part 2 production observed By Ebonold opened the purchase price of 33.55 yuan / share Ebonold 20 officially opened the COMPANY board IPO purchase, determine the issue price of 33.55 yuan / share, the corresponding price-earnings ratio of 55.55 times.
the proposed fund raising of 800 million yuan, of which 262 million yuan for ophthalmic lenses and supporting products capacity expansion and automation upgrading projects, 215 million yuan for high-end ophthalmological medical equipment and high-value consumables research and development pilot projects, 152 million yuan for marketing network and information construction projects, 170 million yuan for supplementary working capital projects.
(Pharmaceutical Rubik's Cube) Beida Pharmaceuticals market value of 60 20 days, Beida Pharmaceuticals open edifada shares continued to fall, as of 11:30 a.m., the official decline, at 134.79 yuan, the overall net outflow of funds of 209 million yuan, market value loss of 6 billion yuan, from 60 billion market value to 54 billion, the pharmaceutical manufacturing industry ranked first.
(Pharmaceutical Intelligence Network) GSK has reached a partnership of more than $1 billion in cooperation with CureVac to develop the mRNA vaccine, GSK and CureVac jointly announced that they have signed a strategic cooperation agreement to jointly research, develop, manufacture and commercialize up to five mRNA vaccines and monoclonal antibodies for infectious disease pathogens.
(Sina Pharmaceutical News) Baiji Shenzhou and Assembly reached a cooperation to introduce 3 HBV core inhibitors into China to develop Baiji Shenzhou and Assembly Biosciences recently jointly announced that the two sides have reached a cooperation in China on the development pipeline of assembly 3 clinical phase core inhibitors for the treatment of chronic hepatitis B infection.
under the terms of the agreement, Assembly will grant Baiji Shenzhou exclusive rights to develop and commercialize ABI-H0731, ABI-H2158 and ABI-H3733 in China, including Hong Kong, Macao and Taiwan.
(Bio-Valley) drug Mingjuno acquired Syracuse plus code solid tumor T cell immunotherapy research and development 20, the drug Mingjuno announced the completion of the acquisition of Syracuse Biopharma, and obtained Eureka Therapeutics proprietary for solid tumor artEMIS ® antibody TCR technology licensing in China and Southeast Asian countries.
hopes to accelerate the development of immunotherapy for solid tumor T cells.
(Pharmaceutical Mission) China Ping An Insurance and Yanye Yi Pharmaceuticals recently reached nearly 3 billion yuan cooperation, Japan's Yinya I Pharmaceuticals announced on its official website that it has reached an agreement with Ping An Insurance, China Ping An Insurance, will jointly contribute nearly 3 billion yuan to set up a joint venture in Shanghai.
the two sides will cooperate through the new company in the field of pharmaceutical research and development platform construction, pharmaceutical quality management and circulation.
(E drug manager) Part 3 drug information In-UK two new crown vaccine clinical trial results can induce an immune response on the 20th local time, The Lancet released the latest results of two new coronavirus vaccine Phase 1/2 clinical trials. one of the
was developed by the Chinese Academy of Engineering's Chen Wei academician team and Kang Sino, and the other was developed by Oxford University and AstraZeno.
from the experimental results, both vaccines can achieve an immune response to the new coronavirus, and induce an efficient T-cell immune response.
(Bioexploration) For Aggressive Acute Treatment BioXcel Therapeutics has announced that its two key Phase III studies in the psychiatry drug BXCL501 (right-meme tongue hypothuminometer) have reached major and secondary endpoints.
results show that in patients with schizophrenia and bipolar disorder, BXCL501 is used for acute treatment with strong therapeutic effect, can quickly and lastingly reduce the intensity, good tolerance.
(Sina Pharmaceutical News) For patients with specific gene mutations, CF triple therapy Trikafta Phase III clinical end 20, Vertex Pharmaceuticals announced Trikafta in patients 12 years of age and older with specific gene mutations in the results of phase 3 clinical studies.
from baseline examination to 8 weeks of treatment, the study reached the main endpoint of the group's predicted percentage change in the amount of force exhalation of 1 second.
at the same time, the study reached all secondary endpoints, including a decrease in the average of the group's sweat chloride slower than the baseline value.
(Sina Pharmaceutical News) Chihong PharmaceuticalZH206 Injection scored for the clinical trial notice ChiHong Pharmaceuticals issued a notice that recently, the company and holding subsidiary Jiangsu Zhonghong Bio jointly applied for a class of new drug ZHB206 injection seisiscope by the State Drug Administration issued a clinical trial notice.
(Sina Pharmaceutical News) Cornbey hydrochloric acid ammonia broso oral solution was registered with the drug approval Zhejiang Kangenbei issued a notice that recently, the company's holding subsidiary Zhejiang Cornbei Chinese medicine received the State Drug Administration approved the issuance of the hydrochloric acid ammonia bromoso oral solution "drug registration approval."
the oral solution of hydrochloric acid ambromino is a commonly used drug for phlegm, which has been included in the National Health Insurance Directory (2019 edition), in the category of Class B drugs.
(Sina Pharmaceutical News) Reding Riptinib China listing application was accepted for treatment of gastrointestinal interlooma 20, and ding medicine and Deciphera Pharmaceuticals jointly announced that the State Drug Administration has accepted Riptinib's new drug listing application for the treatment of three or more kinds of kinetics inhibitortreatment of advanced gastrointestinal intercomma adult patients.
(Instant Medicine) New Drug For Type C Neiman-Pike Disease: Arecently, Orphazyme announced that it has completed a rolling application to the FDA for a new drug for arimoclomol, which is used to treat type C Neiman-Pike disease.
Orphazyme also plans to submit a marketing authorization application for arimoclomol therapeutic NPC to the European EMA in the second half of this year.
(BioValley) pioneer nuclear output inhibitor Xpovio 3 indications by the FDA accepted dege pharmaceutical partner Karyop Therapeutics recently announced that the U.S. FDA has accepted Xpovio's application for a new drug, the application to seek approval of a new indication for patients with multiple myeloma who have previously undergone at least one treatment.
(Bio Valley)